Title (en)

HIV-1 TAT, OR DERIVATIVES THEREOF FOR PROPHYLACTIC AND THERAPEUTIC VACCINATION

Title (de)

HIV-1 TAT ODER DEREN DERIVATE FÜR PROPHYLAKTISCHE UND THERAPEUTISCHE IMPFUNG

Title (fr)

TAT DE VIH-1 OU SES DERIVES COMME PRODUIT PROPHYLACTIQUE OU THERAPEUTIQUE DE VACCINATION

Publication

**EP 1035865 A2 20000920 (EN)**

Application

**EP 98966601 A 19981130**

Priority

- EP 9807721 W 19981130
- IT RM970743 A 19971201

Abstract (en)

[origin: WO9927958A2] The present invention refers to Tat as the active principale for a prophylactic and/or therapeutic vaccine against HIV infection, the progression towards AIDS and the development of tumors and other syndromes and symptoms in subjects infected by HIV. Tat is in biologically active form either as recombinant protein or peptide or as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in combination with other genes or viral gene products (Nef, Rev, Gag) or parts thereof, or in combination with various immuno modulant cytokines (IL-12, IL-15) or with the gene coding for an immuno modulant cytokine or part thereof. Tat, Nef, Rev, Gag and the immuno modulant cytokines are administrated both as a mixture of recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, Tat/IL-12, Tat/IL-15) or as plasmid DNA.

IPC 1-7 (main, further and additional classification)

**A61K 39/21**; C07K 14/16; C12N 5/10; C12N 15/49; C12N 15/86

IPC 8 full level (invention and additional information)

**C12N 15/09** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 39/21** (2006.01); **A61K 48/00** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 37/04** (2006.01); **C07K 7/08** (2006.01); **C07K 14/16** (2006.01); **C12N 5/10** (2006.01); **C12N 15/49** (2006.01); **C12P 21/02** (2006.01); **C12P 21/08** (2006.01); **C12Q 1/68** (2006.01); C12R 1/91 (2006.01)

CPC (invention and additional information)

**A61K 39/21** (2013.01); **A61K 39/12** (2013.01); **C07K 14/005** (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/525 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55566 (2013.01); C12N 2710/16043 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16322 (2013.01); C12N 2740/16334 (2013.01)

Citation (search report)

See references of WO 9927958A3

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI NL PT SE

DOCDB simple family

WO 9927958 A2 19990610; WO 9927958 A3 19990722; WO 9927958 A9 19990910; AP 200001828 A0 20000630; AT 374041 T 20071015; AU 2412699 A 19990616; AU 762893 B2 20030710; BR 9814725 A 20001003; CA 2311647 A1 19990610; CA 2311647 C 20130319; CN 1283121 A 20010207; CU 20000126 A7 20051019; CY 1107818 T1 20130619; DE 69838486 D1 20071108; DE 69838486 T2 20080626; DK 1035865 T3 20080204; EA 004330 B1 20040429; EA 200000596 A1 20001225; EP 1035865 A2 20000920; EP 1035865 B1 20070926; EP 1698347 A2 20060906; EP 1698347 A3 20061220; ES 2293700 T3 20080316; IL 136372 D0 20010614; IT 1297090 B1 19990803; IT RM970743 A1 19990601; JP 2001524531 A 20011204; NZ 505373 A 20030725; OA 11419 A 20040421; PL 341818 A1 20010507; PT 1035865 E 20071207; TR 200001553 T2 20001121; US 2010015087 A1 20100121; US 7744896 B1 20100629; US 8197820 B2 20120612